Psoriasis
Conditions
Keywords
Psoriasis, Deucravacitinib
Brief summary
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Psoriasis (PsO) participants who received Deucravacitinib for the first time of the approved indications at medical institutions in Japan will be enrolled in this PMS
Exclusion criteria
* Participants receiving Deucravacitinib for an off-label indication will be excluded from this PMS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events (AEs) | Up to 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in Body Surface Area (BSA) during study period | Up to 52 weeks |
| Proportion of participants achieving Global Improvement Score (GIS) during study period | Up to 52 weeks |
| Distribution of demographic characteristics: Age | Up to 52 weeks |
| Proportion of participants achieving Static Physicians Global Assessment (sPGA) of 0/1 during study period | Up to 52 weeks |
| Distribution of demographic characteristics: Height | Up to 52 weeks |
| Distribution of demographic characteristics: Weight | Up to 52 weeks |
| Distribution of demographic characteristics: Past history /complication | Up to 52 weeks |
| Distribution of demographic characteristics: Sex | Up to 52 weeks |
Countries
Japan
Outcome results
None listed